[CAS NO. 897657-95-3]??MSX-122
PRODUCTS SPECIFICATIONS [897657-95-3]
DESCRIPTION [897657-95-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 292.34 |
| Molecular Formula | C16H16N6 |
| SMILES | C1(CNC2=NC=CC=N2)=CC=C(CNC3=NC=CC=N3)C=C1 |
1 Publications Citing Use of MCE
Summary
MSX-122 is an orally active partial antagonist of CXCR4 , inhibiting CXCR4/CXCL12 actions, with an IC 50 of ～10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.
IC50 & Target
|
CXCR4/CXCL12 ~10 nM (IC 50 ) |
In Vitro
MSX-122 is a partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC 50 of ～10 nM. MSX-122 shows no inhibition on cAMP reduction mediated by their corresponding ligands CCR3/CCL5 and CCR5/CCL5. MSX-122 (100 nM) potently blocks invasion of 78% MDA-MB-231 cells. However, MSX-122 does not suppress T-tropic HIV infection and is inactive in calcium flux assay [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MSX-122 (10 mg/kg, i.p.) blocks inflammation induced by carrageenan and lung fibrosis induced by bleomycin in mice. MSX-122 (4 mg/kg, i.p., daily) blocks metastasis in an experimental animal model of breast cancer metastasis. Furthermore, MSX-122 (10 mg/kg i.p., daily) significantly decreases the numbers of hepatic micrometastases [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00591682 | Metastatix, Inc. |
Solid Tumors
|
November 2007 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 4 mg/mL ( 13.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.4207 mL | 17.1034 mL | 34.2067 mL |
| 5 mM | 0.6841 mL | 3.4207 mL | 6.8413 mL |
| 10 mM | 0.3421 mL | 1.7103 mL | 3.4207 mL |
-
1.
Add each solvent one by one: 0.5% CMC-Na /saline water
Solubility: 10 mg/mL (34.21 mM); Suspended solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.4 mg/mL (1.37 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 0.4 mg/mL (1.37 mM); Clear solution